CSIMarket
 
Gh Research Plc  (GHRS)
Other Ticker:  
 
 
Price: $10.9000 $0.73 7.178%
Day's High: $11.58 Week Perf: 30.38 %
Day's Low: $ 10.09 30 Day Perf: 36.25 %
Volume (M): 98 52 Wk High: $ 14.64
Volume (M$): $ 1,067 52 Wk Avg: $9.08
Open: $10.09 52 Wk Low: $5.05



 Market Capitalization (Millions $) 570
 Shares Outstanding (Millions) 52
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 166
 Capital Exp. (TTM) (Millions $) 0

Gh Research Plc
GH Research PLC is a biotechnology company that is focused on researching, developing, and commercializing advanced therapies for patients with significant unmet medical needs. The company is comprised of a team of experts in the fields of pharmacology, molecular biology, immunology, and genetics, all driven by a common goal to improve patient outcomes.

The company is headquartered in London, England, and it was founded in 200 Since then, GH Research has grown into a leading global biotechnology company that is committed to discovering and developing innovative treatments for patients. The company has research and development centers across the world, with a focus on developing therapies that target chronic diseases, rare diseases, and oncology.

GH Research is dedicated to solving some of the greatest challenges in drug discovery and development. The company's research areas include the development of small molecules, monoclonal antibodies, gene therapies, and immunotherapies. GH Research has several proprietary platforms that enable the identification and development of drug candidates, which includes computational biology, high-throughput screening, and bioinformatics.

The company has a strong focus on innovation and collaboration, working closely with key partners across the industry. GH Research has partnered with leading academic institutions, scientific organizations, and biopharmaceutical companies to optimize drug discovery and development, and to advance the understanding of disease biology.

The company's product pipeline includes a range of innovative therapies in various stages of development, including preclinical and clinical development. GH Research is committed to bringing these therapies to market as quickly and efficiently as possible, with the goal of improving patient outcomes and enhancing quality of life.

Overall, GH Research is a highly innovative and collaborative biotechnology company that is dedicated to solving some of the most significant challenges in drug discovery and development. With a dedicated team of experts, cutting-edge technologies, and a strong focus on developing therapies that address significant unmet medical needs, the company is poised for continued growth and success.


   Company Address: Joshua Dawson House Dublin 2 0
   Company Phone Number: 437 8334   Stock Exchange / Ticker: NASDAQ GHRS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Gh Research Plc

GH Research PLC Faces Significant Operating Losses in Fourth Quarter of 2023 Earnings Season

In the world of Major Pharmaceutical Preparations, industry insiders are currently analyzing the fourth-quarter numbers of 2023. It has come to their attention that Gh Research Plc, a prominent player in the industry, has reported an operating loss of $-41.222 million for the October to December 31, 2023 financial reporting period. It is worth noting that Gh Research Plc has not yet stated any revenue for this period. This operating loss is a significant decline from the fourth quarter of 2022, which reported an operating loss of $-30.554 million. Analysts are now speculating whether Gh Research Plc will begin to cite revenue and reverse this trend.
It is not uncommon for companies to face challenging periods while striving to establish a successful business strategy. The fourth quarter of 2023 has proven to be one of these difficult periods, with shortfalls expanding to $-35.587 million. During the fiscal year 2023, the Major Pharmaceutical Preparations company announced a loss of $-35.59 million and zero revenue. This represents a wider net loss per share of $-0.68, compared to $-0.43 in the preceding fiscal year, with no revenue growth from the previous year.

Product Service News

GH Research Receives European Patent for Groundbreaking Treatment of Depression with Mebufotenin (5-MeO-DMT) and Salt Products

Published Thu, Jan 18 2024 9:31 PM UTC

GH Research Receives European Patent for Mebufotenin (5-MeO-DMT) and Salt Products in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionDUBLIN, Ireland, Jan. 18, 2024 - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of psychiatric and neurological disorders, announced today that i...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com